Quantum News
Sign InSign Up
Back to News
research

Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Allogene Therapeutics announced interim futility analysis results from its Phase II ALPHA3 trial for first-line consolidation large B-cell lymphoma on April 13, 2026, revealing the study failed to meet predefined efficacy thresholds. CEO David Chang and CMO Zachary Roberts led the update, confirming the trial’s independent data monitoring committee recommended continuation despite underwhelming early data, citing potential long-term benefits. The trial evaluates Allogene’s allogeneic CAR-T therapy, a key alternative to autologous treatments, aiming to improve accessibility and reduce costs for lymphoma patients post-chemotherapy. Analysts from Goldman Sachs, TD Cowen, and Citigroup questioned the therapy’s viability, pressing executives on safety profiles and next steps, including possible trial modifications or pivot strategies. Allogene plans to release full data later in 2026, with leadership emphasizing ongoing commitment to allogeneic CAR-T development despite the setback.
AI Audio Summary
0:00 / 0:00
Click to play
Generate images of quantum computing to be used as banner image for articles.jpg
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts159.27K FollowersFollow5ShareSaveComments Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma April 13, 2026 8:30 AM EDT Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy OfficerDavid Chang - Co-Founder, President, CEO & DirectorZachary Roberts - Executive VP of Research & Development and Chief Medical Officer Conference Call Participants Jeff SharmanSalveen Richter - Goldman Sachs Group, Inc., Research DivisionTyler Van Buren - TD Cowen, Research DivisionSamantha Semenkow - Citigroup Inc., Research DivisionMichael Yee - UBS Investment Bank, Research DivisionMatthew Phipps - William Blair & Company L.L.C., Research DivisionJiale Song - Jefferies LLC, Research DivisionMatthew Biegler - Oppenheimer & Co. Inc., Research Division Presentation Operator Hello, and thank you for standing by, and welcome to Allogene Therapeutics Business Update Conference Call. [Operator Instructions] Please be aware that today's conference call is being recorded. I would now like to turn the call over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer. Ms. Cassiano, please go ahead. Christine CassianoExecutive VP, Chief Corporate Affairs & Brand Strategy Officer Thank you, operator, and welcome to Allogene's conference call. This morning, Allogene issued a press release announcing data from our interim futility analysis from the pivotal Phase II ALPHA3 trial in first-line consolidation large B-cell lymphoma. This press release, webcast and accompanying slides are available on our website. Following our prepared remarks, we will host a Q&A session, and we'll keep the call to an hour. I'm joined today by Dr. David Chang, President and Chief Executive Officer; Dr. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer; Jeff Parker, Chief Financial Officer; and Dr. Jeff Sharman, Chair of the Lymphoma Research Executive Committees SCRI at Willamette Valley Cancer Institute & Research Center. After opening remarks by Dr. Chang, Dr. Roberts will walk you through the key highlights of the interim futility

Read Original

Tags

quantum-finance

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.